GT BIOPHARMA INC (GTBP) Fundamental Analysis & Valuation

NASDAQ:GTBP • US36254L3087

Current stock price

0.369 USD
-0.02 (-5.46%)
At close:
0.375 USD
+0.01 (+1.63%)
After Hours:

This GTBP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. GTBP Profitability Analysis

1.1 Basic Checks

  • GTBP had negative earnings in the past year.
  • GTBP had a negative operating cash flow in the past year.
  • GTBP had negative earnings in each of the past 5 years.
  • GTBP had a negative operating cash flow in each of the past 5 years.
GTBP Yearly Net Income VS EBIT VS OCF VS FCFGTBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M -250M

1.2 Ratios

  • GTBP has a Return On Assets of -710.67%. This is amonst the worse of the industry: GTBP underperforms 94.97% of its industry peers.
  • GTBP's Return On Equity of -1023.60% is on the low side compared to the rest of the industry. GTBP is outperformed by 81.24% of its industry peers.
Industry RankSector Rank
ROA -710.67%
ROE -1023.6%
ROIC N/A
ROA(3y)-163.21%
ROA(5y)-233.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GTBP Yearly ROA, ROE, ROICGTBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10K 20K 30K

1.3 Margins

  • GTBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GTBP Yearly Profit, Operating, Gross MarginsGTBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. GTBP Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for GTBP has been increased compared to 1 year ago.
  • The number of shares outstanding for GTBP has been increased compared to 5 years ago.
  • There is no outstanding debt for GTBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GTBP Yearly Shares OutstandingGTBP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
GTBP Yearly Total Debt VS Total AssetsGTBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • GTBP has an Altman-Z score of -234.33. This is a bad value and indicates that GTBP is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -234.33, GTBP is not doing good in the industry: 94.97% of the companies in the same industry are doing better.
  • There is no outstanding debt for GTBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -234.33
ROIC/WACCN/A
WACCN/A
GTBP Yearly LT Debt VS Equity VS FCFGTBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • A Current Ratio of 3.27 indicates that GTBP has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.27, GTBP is not doing good in the industry: 60.73% of the companies in the same industry are doing better.
  • GTBP has a Quick Ratio of 3.27. This indicates that GTBP is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.27, GTBP perfoms like the industry average, outperforming 41.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.27
Quick Ratio 3.27
GTBP Yearly Current Assets VS Current LiabilitesGTBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. GTBP Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-191.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 15.87% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y88.98%
EPS Next 2Y38.5%
EPS Next 3Y22.32%
EPS Next 5Y15.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GTBP Yearly Revenue VS EstimatesGTBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2029 2030 2031 20B 40B 60B 80B
GTBP Yearly EPS VS EstimatesGTBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

1

4. GTBP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GTBP. In the last year negative earnings were reported.
  • Also next year GTBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GTBP Price Earnings VS Forward Price EarningsGTBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GTBP Per share dataGTBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as GTBP's earnings are expected to grow with 22.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.5%
EPS Next 3Y22.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GTBP Dividend Analysis

5.1 Amount

  • GTBP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GTBP Fundamentals: All Metrics, Ratios and Statistics

GT BIOPHARMA INC

NASDAQ:GTBP (4/10/2026, 8:28:19 PM)

After market: 0.375 +0.01 (+1.63%)

0.369

-0.02 (-5.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)05-13
Inst Owners3.08%
Inst Owner Change0.02%
Ins Owners0.92%
Ins Owner Change0%
Market Cap11.64M
Revenue(TTM)N/A
Net Income(TTM)-30.71M
Analysts82.86
Price Target3.06 (729.27%)
Short Float %3.36%
Short Ratio0.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.02
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-39.39%
Min EPS beat(2)-103.82%
Max EPS beat(2)25.03%
EPS beat(4)2
Avg EPS beat(4)-8.58%
Min EPS beat(4)-103.82%
Max EPS beat(4)49.45%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-62.5%
PT rev (3m)-62.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.88
P/tB 3.88
EV/EBITDA N/A
EPS(TTM)-6.48
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -710.67%
ROE -1023.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-163.21%
ROA(5y)-233.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.27
Quick Ratio 3.27
Altman-Z -234.33
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-191.57%
EPS Next Y88.98%
EPS Next 2Y38.5%
EPS Next 3Y22.32%
EPS Next 5Y15.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-98952%
EBIT Next 3Y-913.74%
EBIT Next 5YN/A
FCF growth 1Y-2.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.32%
OCF growth 3YN/A
OCF growth 5YN/A

GT BIOPHARMA INC / GTBP Fundamental Analysis FAQ

What is the fundamental rating for GTBP stock?

ChartMill assigns a fundamental rating of 2 / 10 to GTBP.


What is the valuation status for GTBP stock?

ChartMill assigns a valuation rating of 1 / 10 to GT BIOPHARMA INC (GTBP). This can be considered as Overvalued.


Can you provide the profitability details for GT BIOPHARMA INC?

GT BIOPHARMA INC (GTBP) has a profitability rating of 0 / 10.


Can you provide the financial health for GTBP stock?

The financial health rating of GT BIOPHARMA INC (GTBP) is 6 / 10.